Hologic Inc. (HOLX) is expected to report Q3 earnings before market open Thursday, July 31, with a conference call scheduled for 9:00 am ET.
Analysts are looking for a profit of 29c on revenue of $435.81M. The consensus is 28c to 31c for EPS, and revenue of $429.60M to $442.30M, according to First Call.
For Q2, Hologic reported EPS 22c vs. consensus of 28c and revenue $431M vs. consensus of $418.09M. Possible drivers for this quarter's earnings will most likely be digital mammography equipment. Possible negatives for earnings period include costs of acquisitions and competition from significantly larger companies in the same product space.
On July 29, Oppenheimer noted that the company's results for its Q3 might exceed expectations. The firm predicts that Hologic's stock will rise over the next six months if the company reports a "clean" quarter, and it maintained an Outperform rating. On July 6, Leerink Swann noted it is bullish on stock ahead of earnings. With Selenia's superior image quality, PACS interface and tomo's pending launch, Leerink thinks the stock is well-positioned to be able to gain market share. The firm Reiterated its Outperform rating.